Alyeska Investment Group
IBRX icon

Alyeska Investment Group’s ImmunityBio IBRX Stock Holding History

Alyeska Investment Group’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-50,000
Closed -$573K – 418
2015
Q3 		$573K Buy
+50,000
New +$1.09M 0.01% 422

Other funds holding IBRX

WCM
Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return
CC
Callan Capital La Jolla, California $1.35B AUM 8.35% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Alyeska Investment Group's IBRX Position: Q4 2015 in Review

Alyeska Investment Group sold out of ImmunityBio (IBRX) in Q4 2015, closing a stake of 50,000 shares — an estimated $573K sold.

Alyeska Investment Group first reported a position in IBRX in Q3 2015 and held it in 1 quarter. The position peaked at $573K in Q3 2015. 61 funds tracked by Wall St. Rank hold IBRX as of Q4 2015.

  • Alyeska Investment Group reported no remaining ImmunityBio position as of Q4 2015 after selling out during the quarter.
  • Alyeska Investment Group sold 50,000 ImmunityBio shares in Q4 2015, an estimated $573K.
  • Alyeska Investment Group first reported a position in ImmunityBio in Q3 2015 and held it in 1 quarter.
  • Alyeska Investment Group's ImmunityBio position peaked at $573K in Q3 2015.
  • 61 funds tracked by Wall St. Rank held ImmunityBio as of Q4 2015.

Based on Alyeska Investment Group's 13F filing for Q4 2015, filed 16 Feb 2016.